You are here

Nanoparticle scavengers for medical countermeasures against mycotoxin

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41GM106952-01
Agency Tracking Number: R41GM106952
Amount: $234,880.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIGMS
Solicitation Number: PA12-089
Timeline
Solicitation Year: 2013
Award Year: 2013
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
1 RIVERSIDE CIRCLE
ROANOKE, VA 24016-
United States
DUNS: 627132913
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 ZHIGUO ZHOU
 (540) 769-8400
 submissions307@lunainnovations.com
Business Contact
 MAGGIE HUDSON
Phone: (434) 483-4254
Email: submissions307@lunainnovations.com
Research Institution
 VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY
 
VIRGINIA POLYTECHNIC INST AND ST UNIV SPONSORED PROGRAMS 0170 300 TURNER STREET NW, SUITE 4200
BLACKSBURG, VA 24061-
United States

 () -
 Nonprofit College or University
Abstract

DESCRIPTION (provided by applicant): Mycotoxin is naturally occurring and is a toxic small molecule produced by fungi. These fungal toxins are representative of a large number of lipophilic agents that pose significant acute and chronic dangers to militarycombatants as potential warfare agents. There are many examples of mycotoxins, some more acutely potent than others. Mycotoxin is classified as hepatotoxins, nephrotoxins, neurotoxins, immunotoxins, and carcinogens. Mycotoxin could also be a threat to thepublic health due to food, water or air contamination. Currently, there are no treatments for mycotoxin exposure in either the acute or chronic setting, and the lack of an effective therapeutic could be catastrophic. In order to protec the safety and health of military personnel and civilians, there is a need to develop a therapeutic and prophylactic drug, which can effectively reduce concentrations below its toxic level and minimize the incidence of clinical toxicity. Luna proposes to develop nanoparticle scavengers that can efficiently sequester the lipophilic mycotoxins in vivo and facilitate their clearance. Ths nanotechnology-based approach offers the potential to treat people under suspicion of actual or potential mycotoxin poisoning. Phase I effortswill focus on demonstrating proof-of-concept in vivo efficacy at attenuating mycotoxin-induced acute toxicities, and demonstrating the safe use of Luna's nanoparticles in one rodent species. Phase II efforts will focus on IND-enabling preclinical studies.Success of the program will provide a valuable medical countermeasure tool against mycotoxins, and it may also find clinical applications for other lipophilic toxins or for overdosed drug toxicities. The nanoparticle antidotes could be important for the Strategic National Stockpile in preparing for an emergency involving bioterrorism. Thus, this proposed technology is of great interest to the public health, and also enhances the nation's preparedness against potential mycotoxin attacks. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Mycotoxin is naturally occurring and is a toxic small molecule produced by organisms of the fungus kingdom, and it is representative of a large number of lipophilic molecular agents that pose significant acute and chronic dangers to military combatants as potential biochemical warfare agents. There are no current treatments for exposure to such agents, and in a potential event of mycotoxin attack, the lack of an effective therapeutic could be catastrophic. This project proposes the development scavenging nanoparticle based medical countermeasures that are capable of efficiently sequestering lipophilic mycotoxins, and facilitating their excretion in vivo resulting in reduced toxicities.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government